The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama sheds light on the pharmaceuticals industry behind them ...

Victoza offers a second option in these cases, he added. Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Ozempic and similar drugs are advertised all over the place, from television ads, public transit, audio streaming platforms ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.